2011

Welcome to Volume 10, Issue #2 (JANUARY 19, 2011) of Pharma Marketing News.

No doubt you've heard that as of August 15, 2011, Facebook opened up comments on ALL pharma pages with some exceptions. That means that the pharmaceutical industry will no longer be able to shut off comments on their Facebook pages.

Social media occupied a good deal of our attention in 2010 and many of the pharma people Pharmaguy met and interacted with in 2010 are involved in social media campaigns in one way or another.

Welcome to Volume 10, Issue #10 (8 JUNE 2011) of Pharma Marketing News.

How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?

The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.

This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.

Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.

Pharmaceutical marketers have jumped on the mobile application bandwagon as more and more companies roll out health-related applications for smartphones and touchpads such as Apple's iPhone and iPad. But will the FDA regulate certain smartphone apps as medical devices? This article discusses the regulatory and other issues associated with pharma developed or sponsored health apps.

Welcome to Volume 10, Issue #9 (18 MAY 2011) of Pharma Marketing News.